English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 28 July 2020, 11:00 HKT/SGT
Share:
    

Source: Theragen Bio Co Ltd
Theragen Bio analyzes Korea's largest COVID-19 patient and coronavirus genomic data

SEOUL, S.KOREA, July 28, 2020 - (ACN Newswire) - Theragen Bio is conducting joint research on developing a new coronavirus (COVID-19) genomic big data in collaboration with the Korea Research Institute of Chemical Technology (KRICT), Kyungpook National University Hospital, and the Daegu Metropolitan Government.




The study will analyze the full genome of each patient and the SARS-CoV-2 virus using samples from approximately 1,000 COVID-19 patients in Daegu and Gyeongsangbuk-do provence, the largest coronavirus genomic analysis to be conducted in Korea.

Through this study, Theragen hopes to identify the infection correlation between patient genome and the SARS-CoV-2 virus genome, and apply it to future vaccine development. Theragen identified the genetic correlation while establishing big data for SARS-CoV-2 mutations.

Based on its own Next Generation Sequencing (NGS), Theragen's ultra-sensitive Covid-19 RNA analysis system can decode over 30,000 full-legnth RNA sequences per virus. The SARS-CoV-2 virus mutates frequently, however the system can check RNA mutation, replication, and generation.

In addition, the evolution of the SARS-CoV-2 virus can be traced back to understand the transmission mechanisms between humans and predict clinical patterns, identify high-risk groups, improve the efficiency of PCR-based diagnosis, and secure evidence for prevention and prevention strategies.

Hwang Tae-soon, the CEO of Theragen Bio, explains, "This research is the first attempt to analyze whether there are differences in infection susceptibility depending on the genetic predisposition of infected patients as well as mutations and the evolution of the virus. It will be applicable to various infectious diseases in the future, as well as clinical prediction and vaccine development."

In April, Theragen Bio collaborated on research for a high-resolution genetic map of SARS-CoV-2, developed by Narry Kim, head of the RNA research group at the Institute for Basic Science (IBS), Hyeshik Chang, a professor at the Department of Biological Sciences, Seoul National University, in collaboration with Korea National Institute of Health (KNIH) within Korea Centers for Disease Control & Prevention (KCDC).

This study found the location of the coronavirus gene and RNA variations, to identify the transcriptome composition and the proliferation principles of the virus. In May, Theragen Bio traced the Seoul Itaewon cluster infections by sequencing the genomic materials and RNA transcriptomes and found that this SARS-CoV-2 variation originated in the U.S.

Theragen Bio, formerly the genome division of Theragen Etex (Kosdaq:066700), was spun off in March, 2020 to actively pursue customized pharmaceutical & new drug development and other projects featuring genomic technology. For further iniformation, please visit www.theragenbio.com.

Contact: Hyun Kim
Theragen Bio Co., Ltd.
Tel: +82-31-888-9313
Email: [email protected]
Website: www.theragenbio.com


Topic: Press release summary
Sectors: Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
Tianzow Breeding (1248.HK) harnesses a favourable industry situation by bringing three cornerstone investors into the market  
Oct 29, 2020 12:55 HKT/SGT
DENSO Announces First-half Financial Results  
Oct 29, 2020 11:57 HKT/SGT
TANAKA Receives 2020 Technology Award from Catalyst Manufacturers Association, Japan  
Oct 29, 2020 10:00 HKT/SGT
MITSUBISHI MOTORS Starts Production of XPANDER in Malaysia  
Oct 29, 2020 08:03 HKT/SGT
Asian Logistics, Maritime and Aviation Conference Goes Online  
Oct 28, 2020 17:00 HKT/SGT
Endowus launches Fund Smart for Singapore investors  
Oct 28, 2020 17:00 HKT/SGT
Trials of Jointly Developed Compact LNG Filling System to Commence in Hokkaido  
Oct 28, 2020 09:30 HKT/SGT
Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the 13th Clinical Trials on Alzheimer's Disease Conference  
Oct 28, 2020 09:07 HKT/SGT
Eisai and JD Health Establish JV Company in China to Implement Health Service Platform  
Oct 28, 2020 08:01 HKT/SGT
Biotechs get scalable early to late phase clinical offering from Avance Clinical and Cromos Pharma - announced at Bio-Europe 2020  
Oct 28, 2020 00:03 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8575